Circulating tumour cells in cancer patients: challenges and perspectives.

By K. Pantel, C. Alix‐Panabières. Trends in Molecular Medicine, 2010

769 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/868bd4f738efb505a698df6585b52d2020f0b8e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Pantel
2. C. Alix‐Panabières
3. D. Hoon
4. J. Condeelis
5. H. Schwarzenbach

In Oncology

1. C. Alix‐Panabières
2. K. Pantel
3. J. Condeelis
4. E. Roussos
5. A. Patsialou
6. J. Pollard
7. Lisa M. Coussens

Citations in the corpus

• Cell-free nucleic acids as biomarkers in cancer patients (2011, background): “cfDNA and micrometastatic cells Besides numerous studies on the clinical utility of circulating tumour cells (CTCs) in blood, disseminated tumour cells (DTCs) in the bone marrow and cfNA in the blood of cancer patient”
• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “Since blood contacts most of the tumors, LBs mostly involve blood sampling, although other body fluids like mucosa, pleural effusions, urine, and cerebrospinal fluid (CSF) are also analyzed [5].”
• Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “The liquid biopsy concept was introduced for circulating tumor cells (CTC) 10 years ago (1) and rapidly extended to circulating tumor DNA (ctDNA; ref.”
• Chemotaxis in cancer (2011, background): “CTCs can be found in the blood of patients years or decades after the removal of their primary tumou”